Literature DB >> 26065866

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis.

Venkatesh Mani1, Nadia Alie2, Sarayu Ramachandran2, Philip M Robson2, Cecilia Besa2, Gregory Piazza3, Michele Mercuri4, Michael Grosso4, Bachir Taouli2, Samuel Z Goldhaber3, Zahi A Fayad2.   

Abstract

We evaluated a magnetic resonance venography (MRV) approach with gadofosveset to quantify total thrombus volume changes as the principal criterion for treatment efficacy in a multicenter randomized study comparing edoxaban monotherapy with a heparin/warfarin regimen for acute, symptomatic lower extremities deep vein thrombosis (DVT) treatment. We also used a direct thrombus imaging approach (DTHI, without the use of a contrast agent) to quantify fresh thrombus. We then sought to evaluate the reproducibility of the analysis methodology and applicability of using 3D magnetic resonance venography and direct thrombus imaging for the quantification of DVT in a multicenter trial setting. From 10 randomly selected subjects participating in the edoxaban Thrombus Reduction Imaging Study (eTRIS), total thrombus volume in the entire lower extremity deep venous system was quantified bilaterally. Subjects were imaged using 3D-T1W gradient echo sequences before (direct thrombus imaging, DTHI) and 5 min after injection of 0.03 mmol/kg of gadofosveset trisodium (magnetic resonance venography, MRV). The margins of the DVT on corresponding axial, curved multi-planar reformatted images were manually delineated by two observers to obtain volumetric measurements of the venous thrombi. MRV was used to compute total DVT volume, whereas DTHI was used to compute volume of fresh thrombus. Intra-class correlation (ICC) and Bland Altman analysis were performed to compare inter and intra-observer variability of the analysis. The ICC for inter and intra-observer variability was excellent (0.99 and 0.98, p <0.001, respectively) with no bias on Bland-Altman analysis for MRV images. For DTHI images, the results were slightly lower (ICC = 0.88 and 0.95 respectively, p <0.001), with bias for inter-observer results on Bland-Altman plots. This study showed feasibility of thrombus volume estimation in DVT using MRV with gadofosveset trisodium, with good intra- and inter-observer reproducibility in a multicenter setting.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26065866      PMCID: PMC4544497          DOI: 10.3791/52761

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

Review 1.  DVT and pulmonary embolism: Part I. Diagnosis.

Authors:  Dino W Ramzi; Kenneth V Leeper
Journal:  Am Fam Physician       Date:  2004-06-15       Impact factor: 3.292

2.  Magnetic resonance VIBE venography using the blood pool contrast agent gadofosveset trisodium--an interrater reliability study.

Authors:  Alexander Pfeil; Stefan Betge; Guenther Poehlmann; Joachim Boettcher; Robert Drescher; Ansgar Malich; Gunter Wolf; Hans-Joachim Mentzel; Andreas Hansch
Journal:  Eur J Radiol       Date:  2011-02-23       Impact factor: 3.528

3.  A volumetric index for the quantification of deep venous thrombosis.

Authors:  K Ouriel; R K Greenberg; R M Green; J M Massullo; D R Goines
Journal:  J Vasc Surg       Date:  1999-12       Impact factor: 4.268

Review 4.  Diagnostic management of acute deep vein thrombosis and pulmonary embolism.

Authors:  M V Huisman; F A Klok
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

5.  A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limbs.

Authors:  Antoine Elias; Luc Mallard; Marie Elias; Catherine Alquier; François Guidolin; Bruno Gauthier; Alain Viard; Pierre Mahouin; Anne Vinel; Henri Boccalon
Journal:  Thromb Haemost       Date:  2003-02       Impact factor: 5.249

6.  Magnetic resonance direct thrombus imaging of the evolution of acute deep vein thrombosis of the leg.

Authors:  R E Westerbeek; C J Van Rooden; M Tan; A P G Van Gils; S Kok; M J De Bats; A De Roos; M V Huisman
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

7.  Gadofosveset: the first intravascular contrast agent EU-approved for use with magnetic resonance angiography.

Authors:  Mathias Goyen
Journal:  Future Cardiol       Date:  2007-01

Review 8.  Venous thromboembolism: epidemiology and magnitude of the problem.

Authors:  Samuel Z Goldhaber
Journal:  Best Pract Res Clin Haematol       Date:  2012-08-09       Impact factor: 3.020

9.  Detection of thrombus size and protein content by ex vivo magnetization transfer and diffusion weighted MRI.

Authors:  Alkystis Phinikaridou; Ye Qiao; Nick Giordano; James A Hamilton
Journal:  J Cardiovasc Magn Reson       Date:  2012-06-25       Impact factor: 5.364

10.  In vivo magnetization transfer and diffusion-weighted magnetic resonance imaging detects thrombus composition in a mouse model of deep vein thrombosis.

Authors:  Alkystis Phinikaridou; Marcelo E Andia; Prakash Saha; Bijan Modarai; Alberto Smith; René M Botnar
Journal:  Circ Cardiovasc Imaging       Date:  2013-04-05       Impact factor: 7.792

View more
  2 in total

1.  Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.

Authors:  Gregory Piazza; Venkatesh Mani; Samuel Z Goldhaber; Michael A Grosso; Michele Mercuri; Hans J Lanz; Steven Schussler; Ching Hsu; Amy Chinigo; Bruce Ritchie; Venkatesh Nadar; Kevin Cannon; John Pullman; Mauricio Concha; Marlin Schul; Zahi A Fayad
Journal:  Vasc Med       Date:  2016-05-10       Impact factor: 3.239

2.  Combined MR direct thrombus imaging and non-contrast magnetic resonance venography reveal the evolution of deep vein thrombosis: a feasibility study.

Authors:  I A Mendichovszky; A N Priest; D J Bowden; S Hunter; I Joubert; S Hilborne; M J Graves; T Baglin; D J Lomas
Journal:  Eur Radiol       Date:  2016-08-30       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.